Risperidone reduces limited access alcohol drinking in alcohol-preferring rats

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Research

Background:

• Ethanol consumption is a significant public health concern.
• Animal models are crucial for understanding the neurobiological underpinnings of alcohol preference and intake.
• Identifying novel pharmacological interventions for alcohol use disorder is a priority.

Purpose of the Study:

• To investigate the effects of the atypical antipsychotic drug risperidone on ethanol consumption in ethanol-preferring rats.
• To determine the dose-dependency and duration of risperidone's effects on alcohol intake.
• To assess the selectivity of risperidone's effects on ethanol consumption versus other behaviors.

Main Methods:

• Utilized the Alko, Alcohol (AA) rat model, known for high ethanol preference.
• Administered risperidone in a limited access paradigm to assess ethanol drinking.
• Evaluated dose-dependent effects on locomotor activity and saccharin intake to assess selectivity.
• Examined short-term and long-term effects of different risperidone doses.

Main Results:

• Risperidone significantly reduced ethanol drinking in AA rats.
• The effect was transient at a low dose (0.1 mg/kg) targeting 5-HT(2) receptors.
• A higher dose (1.0 mg/kg), also blocking dopamine D(2) receptors, produced a long-lasting reduction in ethanol intake.
• Risperidone also reduced locomotor activity and saccharin intake, indicating non-selective effects.

Conclusions:

• Risperidone demonstrates efficacy in reducing ethanol consumption in an animal model of high alcohol intake.
• The duration of action appears dependent on the dose and receptor antagonism profile.
• These findings support further investigation of risperidone as a potential therapeutic agent for alcohol use disorder in human populations.